Linn Energy Is a Buy
Health Care: Drugs
Bioline Rx Ltd. (BLRX: NASDAQ)
$1.67 -0.08 | -4.57%
05/22/13 - 03:58 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.75 |
| 52 Week High | 5.10 |
| 52 Week Low | 1.59 |
| Avg. Daily Vol. (Mil) | 0.22 |
| Beta (3 year) | 0.00 |
| Share Related Items | |
| Mkt Cap (Mil) | 38.95 |
| Shares Out (Mil) | 22.26 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | n.a. |
| Financial Strength | |
| Quick Ratio | n.a. |
| Current Ratio | n.a. |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 0.00 |
| Price/Cash Flow | n.a. |
| Per Share Data | |
| Earnings | 0.00 |
| Sales | 0.00 |
| Book Value | 0.00 |
| Cash Flow | n.a. |
| Business Summary | |
|---|---|
| Bioline Rx Ltd. is a clinical-stage biopharmaceutical development company engaged in identifying, in-licensing & developing therapeutic compounds in areas of central nervous system, oncology, cardiovascular, & infectious diseases, among others. | |
| General Information | |
| 19 Hartum Street
P.O.Box 45158 Jerusalem, 91450 |
|
| www.biolinerx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: NA | |
| CEO: Dr. Kinneret Savitsky, P | |
| Short Interest | |
| Current Month (Mil) | 0.14 |
| Previous Month (Mil) | 0.15 |
| Short Interest Ratio (Days) | 0.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | 0.00 |
| Return on Investments | n.a. |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with BLRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest BLRX Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 04.18.13 | 02:04 pm
- BioLineRx Shares Fall On Schizophrenia Drug Failure 03.20.13 | 10:03 am
- 4 Stocks Under $5 Making Big Moves 02.22.13 | 03:02 pm
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
Press Releases for BLRX
- Oramed Pharmaceuticals Appoints New Chief Operating Officer And VP Of Business Development - PR Newswire 04.16.13 | 09:04 am
- BioLineRx Announces Results From Interim Analysis Of Phase II/III CLARITY Trial Of BL-1020 For Schizophrenia - Business Wire 03.20.13 | 09:03 am
- BioLineRx Receives Approval From French Regulatory Authorities To Commence A Phase I/II Clinical Trial For BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C - Business Wire 03.13.13 | 07:03 am
- BioLineRx Reports Year End 2012 Financial Results - Business Wire 03.12.13 | 07:03 am
- BioLineRx's EDP-14, For Treatment Of Severe And Persistent Asthma, To Enter The Company's Main Therapeutic Pipeline As BL-9010 - Business Wire 02.28.13 | 07:02 am
- BioLineRx To Report Fourth Quarter And Year End 2012 Results On March 12, 2013 - Business Wire 02.26.13 | 07:02 am
- BioLineRx Announces Closing Of $8 Million Offering Of American Depositary Shares - Business Wire 02.13.13 | 07:02 am
- BioLineRx Announces Offering Of American Depositary Shares - Business Wire 02.06.13 | 09:02 am
- BioLineRx Provides Clarification Regarding Interim Analysis Of CLARITY Trial For BL-1020 - Business Wire 02.04.13 | 07:02 am
- BioLineRx To Present At The 2013 BIO CEO & Investor Conference In New York On February 12th - Business Wire 01.31.13 | 07:01 am
Partner Headlines for BLRX
- Morning Market Movers - Benzinga 10.03.12 | 09:10 am
- Healthcare Business Review: Vivus DISSED By Citron, Lundbeck, et al Have OPPORTUNITY - Wall St. Cheat Sheet 07.20.12 | 08:07 am
- Traders are Up and Actively Waving Hands for These 5 Stocks Today - Wall St. Cheat Sheet 06.05.12 | 01:06 pm
- Ultimate Market Recap: GM China Sales Soar, Apple Makes New Macs - Wall St. Cheat Sheet 06.05.12 | 09:06 am
- 5 High-Risk, High-Reward Biopharma Stocks - Seeking Alpha 02.14.12 | 09:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Morning Market Movers - Benzinga 09.13.11 | 09:09 am
